Furthermore, systemic administration of the multi-CDK inhibitor AT7519 (targeting CDK1/2/7/9) has shown favorable tolerability in pancreatic cancer xenograft models, with no significant adverse effects reported [50]. Here, CDK1 is linked to pancreatic neoplasm.